Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting ...( -Combination of a Bavituximab Equival...),Health

-Combination of a Bavituximab Equivalent and an Agent that Re-Activates the Tumor Suppressor P53 Inhibited Tumor Growth Synergistically in Preclinical

Breast Cancer Models-

SAN DIEGO and TUSTIN, Calif., April 14 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) announced today that a preclinical study being presented by an independent team of investigators at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) further illustrates the broad anti-tumor potential of its anti-phosphatidylserine (anti-PS) vascular targeting antibodies. The study by Dr. Yayun Liang, Dr. Salman Hyder and colleagues at the University of Missouri describes promising anti-cancer activity observed when a mouse equivalent to the company's Phase II anti-PS antibody bavituximab was combined with an investigational agent that re-activates the tumor suppressor p53, which is turned off in many tumors. Bavituximab is a monoclonal antibody that is believed to work by selectively destroying the blood vessels supporting tumor growth and spread and by reversing the ability of tumors to suppress the body's natural immune response.

"This study highlights the broad anti-cancer potential of our anti-PS vascular targeting platform," said Steven W. King, president and CEO of Peregrine. "Numerous preclinical studies have shown the potential efficacy of our anti-PS antibodies in combination with both existing and novel therapies for the treatment of cancer. This new study further illustrates the potential versatility of our anti-PS antibodies in combination cancer therapy. We look forward to future clinical studies of bavituximab and other anti-PS antibodies in a broad range of anti-cancer regime
'/>"/>